A new easy way to "clean" pharma ingredients; study

By Natalie Morrison

- Last updated on GMT

Related tags: Active pharmaceutical ingredients, Pharmacology

A new easy way to "clean" pharma ingredients; study
Scientists have uncovered a new simple way to “clean” genotoxic impurities (GTIs) in drug ingredients by mixing the solution with contamination-eating scavengers.

GTIs have been behind several major drug recalls recently – for instance the EU’s 2007 swoop on Roche’s ARV (antiretroviral) med Viracept. The phenomenon is caused by higher than normal levels of toxicity in the potent compounds, intermediates and reagents used to synthesize active pharmaceutical ingredients (APIs).

Now working with the widely-used GTI acrolein, a team from MIP Technologies in conjunction with the University of Dortmund, Germany, found that a silica and polystyrene (PS-NH2​) scavenger resin could remove 97.8 per cent of the impurity given just a 20 minute reaction time.

The process caused no substantial damage to the API.

A growing need

The researchers say the paper, ‘Removal of Acrolein from Active Pharmaceutical Ingredients Using Aldehyde Scavengers’, is a reaction to a growing industry need, specifically after the EMA (European Medicines Agency) issued guidelines on the Limits of Genotoxic Impurities in 2006.

Under the guideline, a 1.5μg per day intake of GTI is considered an “acceptable risk”.

“Pharmaceutical genotoxic impurities (GTIs) may induce genetic mutations, chromosomal breaks, or chromosomal rearrangements, and have the potential to cause cancer in human,”​ the team, led by MIP’s chief technology officer Ecevit Yilmaz, said.

“Therefore, exposure to even low levels of such impurities present in the final API may be of significant toxicological concern.”

The team also said that though the resin is currently readily available – labelling scavenger resins a “a well-known approach” ​– more research must be carried out if the process is to be used on a commercial scale.

The study – published in Organic Process Research & Development​ – looked at other resins besides PS-NH2​, which has a high degree of cross-linking.

It found the less cross-linked polymer-based scavengers are more selective in their scourging, they showed an “undesired high level of nonspecific binding to the API.”

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Related suppliers

Follow us


View more